|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||7.84 - 7.84|
|52 Week Range||5.50 - 9.30|
|Beta (3Y Monthly)||-0.01|
|PE Ratio (TTM)||30.75|
|Earnings Date||Oct 14, 2019 - Oct 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
The Company reported net income for the three months ended May 31, 2019 of $54,000, or $0.01 per basic and diluted share, compared to net income of $540,000, or $0.07 per basic and diluted share for the three months ended May 31, 2018. Net income for the three months ended May 31, 2019 resulted from a 25% increase in revenue offset by a 48% increase in cost of sales and a 3% increase in selling, general and administrative expenses. The increase in cost of sales is due in part to the 23% increase in new domestic cord blood specimens processed in the second quarter of fiscal 2019 versus the same period in 2018 as well as costs associated with public banking.
OLDSMAR, Fla., April 15, 2019 -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and.
Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2018. The revenues for fiscal 2018 consisted of $27.8 million in processing and storage fee revenue, $1.0 million in licensee income, $104,000 in product revenue and $296,000 in public banking revenue compared to $23.9 million in processing and storage fee revenue, $1.0 million in licensee income, $442,000 in product revenue and $0 in public banking revenue for fiscal 2017. Due to the acquisition of Cord:Use Cord Blood Bank, Inc. (“Cord:Use”), the Company now records public banking revenue which is generated from the sale of the donated cord blood units to the National Marrow Donor Program (“NMDP”), which distributes the cord blood units to transplant centers located in the United States and around the world.